PSAWeekly #01

Updates to the 2026 AUA/SUO Guideline on Early Detection of Prostate Cancer: A Comprehensive Summary of Revised Recommendations

In February 2026, the American Urological Association (AUA) and the Society of Urologic Oncology (SUO) published an updated guideline on the early detection of prostate cancer in The Journal of Urology, incorporating new evidence through December 2024 and refining recommendations across screening, imaging, biomarkers, and biopsy technique.

The guideline reaffirms prostate-specific antigen (PSA) as the cornerstone first-line screening test (Strong Recommendation, Grade A), supported by randomized trial data demonstrating its capacity to reduce metastasis and prostate cancer–specific mortality. When a PSA value is first noted to be elevated, the panel advises repeating the measurement before proceeding to secondary biomarkers, imaging, or biopsy. Screening intervals should be individualized based on age, baseline PSA level, and competing health risks. For men around age 60 with a PSA below 1 ng/mL, the long-term risk of metastasis or death from prostate cancer is exceedingly low approximately 0.5% and 0.2% over 25 years, respectively justifying consideration of extended screening intervals or cessation of screening altogether in the absence of additional risk factors. Data from the Göteborg-1 trial and ERSPC further support that continued screening beyond age 68–70 adds minimal benefit for men aged 60 and older with a PSA below 2 ng/mL. For previously screened men aged 75 and older with a PSA below 3 ng/mL, data from the Baltimore Longitudinal Study of Aging and ERSPC Rotterdam suggest that the risk of prostate cancer–specific mortality is sufficiently low to justify discontinuation.

Regarding the digital rectal examination (DRE), the guideline emphasizes that it should not serve as a standalone screening tool in asymptomatic men. A recent meta-analysis demonstrated that adding DRE to PSA-based screening does not meaningfully improve positive predictive value, and survey data indicate that approximately one-quarter of men may forgo screening entirely when upfront DRE is required. Nevertheless, DRE retains a role as an adjunctive tool alongside PSA for risk stratification of clinically significant disease (Conditional Recommendation, Grade C) and remains valuable in the evaluation of symptomatic patients.

One of the most impactful revisions concerns the role of pre-biopsy magnetic resonance imaging (MRI). The guideline now supports MRI prior to initial biopsy to improve detection of clinically significant cancer, defined as Grade Group 2 or higher, with the evidence level upgraded to Grade A (Conditional Recommendation). This recommendation is substantiated by data from multiple prospective trials, including PRECISION, MULTIPROS, Göteborg-2, PROKOMB, and PROBASE. In the Göteborg-2 screening trial, a PSA-plus-MRI pathway permitted men with negative MRI to safely forgo biopsy, reducing detection of clinically insignificant cancer by more than half without excess advanced disease at four-year follow-up. However, the recommendation remains conditional rather than strong due to demonstrated dependence on image quality and radiologist expertise; the PROBASE trial reported that expert central reads achieved 79% sensitivity and 91% negative predictive value (NPV), whereas local reads yielded only 55% sensitivity and 80% NPV.

A novel recommendation addresses patients with negative or equivocal MRI findings who nonetheless harbor elevated risk based on clinical parameters such as PSA density. For these individuals, the guideline advises proceeding with systematic biopsy rather than deferral (Moderate Recommendation, Grade C), supported by evidence that a PSA density threshold of 0.15 ng/mL/cc maintains a 94% NPV for excluding clinically significant disease. The adjunctive use of serum-based biomarkers (4Kscore, PHI, STHLM-3) and urine-based assays (PCA3, SelectMDx, ExoDx, MyProstateScore 2.0) is endorsed when further risk stratification would meaningfully influence the biopsy decision, with these tools generally reducing unnecessary biopsies by approximately one-third while missing roughly 5–10% of clinically significant cancers. Polygenic risk scores remain investigational and should not independently drive biopsy decisions outside structured research protocols.

Following a negative initial biopsy, biomarker-guided strategies may inform the decision regarding repeat biopsy. For example, a MyProstateScore threshold of 40 yields a 95% NPV while avoiding 67% of repeat biopsies, and the MPS2 urine test may obviate half of repeat biopsies while maintaining 95% sensitivity for Grade Group 2 disease. Notably, the management of atypical small acinar proliferation (ASAP) has been upgraded from Expert Opinion to a Moderate Recommendation (Grade C), reflecting pooled data demonstrating a 30–50% risk of cancer on repeat biopsy after an ASAP diagnosis, with approximately 12% representing clinically significant disease. The guideline now explicitly advises that clinicians pursue additional testing including repeat systematic biopsy with or without MRI-targeted biopsy, PSA monitoring, or biomarker assessment following an ASAP finding.

Regarding biopsy technique, both trans-rectal and trans-perineal approaches remain acceptable (Conditional Recommendation, Grade B). Evidence from multiple randomized controlled trials — including PERFECT, PREVENT, PROBE-PC, and the TRANSLATE study demonstrates no statistically significant difference in overall detection rates of clinically significant prostate cancer between the two routes. The TRANSLATE trial reported only a 6% difference favoring the trans-perineal approach, primarily driven by higher detection of Grade Group 2 cancers with no difference in Grade Group 3 or higher. Infection rates were comparable across randomized trials, though trans-perineal biopsy typically requires minimal antibiotic prophylaxis and may confer a specific advantage in patients with prior infectious complications, elevated infection risk, or anterior lesions. Conversely, perineal pain particularly persistent discomfort was more prevalent with the trans-perineal approach, while rectal bleeding and prolonged hematospermia were more frequently associated with the trans-rectal route. The practical choice between approaches should be guided by available equipment, operator expertise, and individual patient factors.

In summary, the 2026 AUA/SUO amendment preserves the core screening paradigm while introducing several evidence-driven refinements that carry meaningful implications for clinical practice most notably the elevation of prebiopsy MRI evidence to Grade A, a new recommendation to proceed with biopsy despite negative MRI when clinical suspicion persists, upgraded ASAP management guidance, an expanded biomarker framework, and a more robust evidence base informing biopsy route selection.

Source: AUA Journals — Updates to Early Detection of Prostate Cancer: What Changed in the 2026 AUA/SUO Guideline.
https://www.auajournals.org/doi/10.1097/JU.0000000000004995

2023 versus 2026 AUA/SUO Early Detection of Prostate Cancer Guidelines: Key Revisions and Clinical Implications

The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) originally published their early detection of prostate cancer guideline in 2023 as a two-part series authored by Wei et al., with Part I addressing screening principles. In 2026, Lin et al. issued a consolidated amendment integrating updates across screening, imaging, biomarkers, biopsy indications, and biopsy technique, incorporating evidence published through December 2024. Although the foundational screening framework remained intact with PSA endorsed as the first-line screening test (Strong Recommendation, Grade A), shared decision-making emphasized throughout, and age-based screening initiation thresholds unchanged several clinically meaningful revisions emerged.

From an epidemiological standpoint, the projected disease burden increased substantially, rising from an estimated 288,300 new diagnoses and 34,700 deaths in 2023 to 333,830 diagnoses and 36,320 deaths in the 2026 update, reflecting approximately 45,000 additional cases and 1,600 additional deaths annually in the United States alone.

Perhaps the most significant revision pertains to prebiopsy magnetic resonance imaging (MRI). Whereas the 2023 Part I guideline did not address this topic, the 2026 amendment formally recommends that clinicians may utilize MRI prior to initial biopsy to enhance detection of Grade Group 2 or higher disease, with the evidence level upgraded to Grade A (Conditional Recommendation). This upgrade is substantiated by several prospective trials, including Göteborg-2, PROKOMB, PROBASE, and MULTIPROS, building upon the earlier PRECISION trial. Notably, the recommendation remains conditional rather than strong owing to demonstrated variability in imaging quality and radiologist expertise; the PROBASE trial reported that expert central MRI reads achieved 79% sensitivity and 91% negative predictive value (NPV), whereas local reads yielded only 55% sensitivity and 80% NPV with moderate interobserver agreement.

An entirely novel recommendation was introduced for patients with negative MRI findings who nonetheless remain at elevated risk for clinically significant cancer. In such cases, the 2026 guideline now advises proceeding with systematic biopsy (Moderate Recommendation, Grade C), supported by a meta-analysis demonstrating that PSA density is the strongest predictor of significant disease in MRI-negative cases, with a threshold of 0.15 ng/mL/cc maintaining a 94% NPV.

Several additional upgrades merit attention. The recommendation following a diagnosis of atypical small acinar proliferation (ASAP) was elevated from Expert Opinion in 2023 to a Moderate Recommendation (Grade C) in 2026, supported by pooled data showing a 12% incidence of Grade Group 2 or higher cancer on repeat biopsy. The evidence base for biopsy technique trans-rectal versus trans-perineal was similarly expanded and upgraded to Grade B, incorporating data from three randomized controlled trials (PERFECT, PREVENT, and PROBE-PC) alongside the TRANSLATE study. While neither approach demonstrated definitive superiority for cancer detection or infection reduction, the update acknowledged the practical shift toward the trans-perineal route driven by concerns regarding antibiotic resistance and sepsis.

The biomarker landscape was also broadened, with the 2026 amendment expanding the biomarker table to include newer assays such as MyProstateScore 2.0 (MPS2) and MiR Sentinel, alongside substantive discussion of polygenic risk scores informed by the BARCODE-1 trial results. The evidence supporting discontinuation of screening was strengthened through incorporation of long-term ERSPC follow-up data, demonstrating that further screening beyond age 68–70 is unlikely to benefit men with PSA levels below 2 ng/mL. Additionally, a newly cited meta-analysis reinforced that digital rectal examination does not significantly improve positive predictive value when added to PSA-based screening.

In summary, the 2026 amendment preserves the core screening paradigm established in 2023 while introducing several evidence-driven refinements most notably the elevation of pre-biopsy MRI to Grade A evidence, a new recommendation to proceed with biopsy despite negative MRI when clinical risk persists, upgraded management guidance for ASAP, expanded biopsy route evidence, and a more comprehensive biomarker framework. These revisions collectively reflect the evolving evidence landscape and carry meaningful implications for contemporary clinical practice in prostate cancer early detection. (Review the attached file)

Source: AUA Journals — 2023 vs. 2026 AUA/SUO Early Detection of Prostate Cancer Guidelines: What Changed?
https://www.auajournals.org/doi/10.1097/JU.0000000000003491Bottom

Intralesional Steroid and Hyaluronidase Injection as an Adjunct to Direct Visual Internal Urethrotomy: Impact on Stricture Recurrence

Direct visual internal urethrotomy (DVIU) remains a widely employed endoscopic intervention for the management of short-segment anterior urethral strictures; however, its long-term efficacy is limited by high recurrence rates. A recent prospective, randomized study investigated whether intralesional injection of triamcinolone combined with hyaluronidase at the urethrotomy site could mitigate this recurrence.

The study enrolled 100 patients with anterior urethral strictures measuring 2 cm or less and randomized them into two cohorts: an intervention group receiving intralesional triamcinolone and hyaluronidase immediately following DVIU, and a control group undergoing DVIU alone. All participants were subsequently instructed in clean intermittent self-dilatation using a 14 Fr Foley catheter. Uroflowmetry assessments were performed at postoperative day 7 and at 1, 3, 6, and 12 months, with treatment success defined as a maximum urinary flow rate (Qmax) exceeding 12 mL/s on a minimum voided volume of 150 mL in the absence of obstructive voiding symptoms.

The findings demonstrated a statistically significant reduction in stricture recurrence in the intervention group (24%) compared with the control group (46%), yielding an absolute risk reduction of 22% (p = 0.021). Furthermore, the mean time to recurrence was significantly prolonged in the intervention cohort (9.4 ± 2.5 months versus 7.5 ± 2.2 months; p = 0.039). Notably, peak urinary flow rates at both 6 and 12 months were significantly superior in the intervention group (15.5 and 14.6 mL/s, respectively) compared with controls (14.6 and 13.6 mL/s; p = 0.006 and p = 0.002, respectively).

These results suggest that the adjunctive use of intralesional triamcinolone and hyaluronidase following DVIU confers a meaningful clinical benefit in terms of reduced recurrence, delayed time to re-stricture, and improved objective urinary flow parameters in patients with short-segment anterior urethral strictures. This approach represents a promising, minimally invasive strategy to enhance the durability of endoscopic urethrotomy outcomes.

Source: Journals of SAGE Publications — Role of intralesional steroid and hyaluronidase injection in reducing recurrence of urethral stricture after direct visual internal urethrotomy: A prospective study.
https://journals.sagepub.com/doi/10.1177/03915603251387896

Efficacy and Safety of Flexible and Navigable Suction Ureteral Access Sheath Versus Conventional Ureteral Access Sheath in Retrograde Intrarenal Surgery: An Updated Systematic Review and Meta‑Analysis

Access sheaths placed through the ureter are a standard tool during flexible ureteroscopic stone procedures, helping with repeated scope entry, better irrigation flow, and reduced kidney pressures. Traditional sheaths, however, have notable drawbacks they cannot actively control renal pressure during long cases and depend on passive drainage for fragment removal, which can lead to dangerous pressure spikes, backflow into the venous system, and subsequent infection. A newer generation of sheaths featuring built-in suction and a steerable tip was engineered to address these gaps. A recently published pooled analysis of comparative data examined whether these advanced sheaths truly outperform their conventional counterparts.

The analysis gathered data from nine clinical comparisons totaling nearly 1,800 patients, including two randomized trials and seven observational studies conducted across multiple continents between 2023 and 2025.

Stone clearance was substantially better with the suction-enabled sheath, showing roughly six-fold higher odds of achieving a stone-free outcome. Every included study pointed in the same direction, with none favoring the traditional device. Postoperative complications mainly low-grade events such as fever, blood in the urine, and mild infections were reduced by approximately two-thirds with the newer sheath, and this finding was remarkably consistent across all studies regardless of design or geographic origin. Meanwhile, surgical duration and length of hospital stay were essentially equivalent between both groups, suggesting the newer technology delivers its advantages without adding time or delaying recovery.

When outcomes were broken down by stone burden, an interesting pattern emerged. For stones measuring 2 cm or less, clearance rates were comparable between devices, though complications were still lower and procedures slightly faster with the suction sheath. For larger stones exceeding 2 cm, the suction sheath appeared to offer a more pronounced advantage in both clearance and safety although this observation rested on limited data requiring further validation.

The proposed explanation centers on three interconnected benefits: the continuous vacuum effect keeps kidney pressures well within safe limits, preventing the harmful backflow that can seed bloodstream infections; ongoing removal of dust and debris maintains a clear operative field, allowing more precise laser work; and the articulating tip follows the scope into hard-to-reach areas of the kidney that rigid devices cannot access effectively.

The authors acknowledged important caveats. Most contributing studies were retrospective, different sheath brands use varying suction strengths and flexibility designs, the definition of "stone-free" was inconsistent across studies, and follow-up was generally limited to three months or less — leaving questions about late complications such as ureteral narrowing unanswered.

In summary, current evidence suggests that suction-capable flexible access sheaths meaningfully improve stone clearance and reduce complications during flexible ureteroscopic stone surgery without extending operative time or hospital stay. The benefit may be greatest for larger, more complex stones. While these findings encourage broader clinical uptake, well-designed prospective multicenter trials with uniform outcome definitions and longer follow-up are still needed before definitive conclusions can be drawn.

Source: Medicina — Efficacy and Safety of Flexible and Navigable Suction Ureteral Access Sheath Versus Conventional Ureteral Access Sheath in Retrograde Intrarenal Surgery: An Updated Systematic Review and Meta-Analysis
https://doi.org/10.3390/medicina62030536

A 34-year-old dermatology colleague approaches you in the physicians' lounge seeking your expert opinion. He explains that he frequently prescribes finasteride 1 mg (Propecia) to male patients for the management of androgenetic alopecia, while he is aware that urologists utilize finasteride 5 mg (Proscar) for benign prostatic hyperplasia. He asks whether the degree of serum prostate-specific antigen (PSA) suppression differs meaningfully between the two dosing regimens, as this information would influence his counseling of patients regarding prostate cancer screening.

Based on the best available evidence, which of the following is the most appropriate response?

A. The 1 mg dose produces approximately half the PSA suppression observed with the 5 mg dose, and therefore no correction factor is required for screening.

B. The 1 mg dose produces negligible PSA suppression, and baseline PSA values can be used without adjustment.

C. Both the 1 mg and 5 mg doses result in a comparable reduction of serum PSA of approximately 50%, and the same correction factor should be applied regardless of the indication.

D. The 5 mg dose produces substantially greater PSA suppression than the 1 mg dose, mandating different correction factors for each regimen.

Rationale: According to D'Amico and Roehrborn (Lancet Oncology, 2007), finasteride at both 1 mg and 5 mg doses produces a similar approximate 50% reduction in serum PSA levels. Consequently, clinicians should apply the same correction factor (multiplication by 2) when interpreting PSA values in men receiving either dose for prostate cancer screening purposes. Therefore the correct answer is C

A 68-year-old man presents to the urology clinic for routine follow-up. He has been maintained on finasteride 5 mg daily for the management of lower urinary tract symptoms secondary to benign prostatic hyperplasia for the past 7 years. His current serum PSA is 3.5 ng/mL. He has no family history of prostate cancer, and digital rectal examination reveals a smooth, symmetrically enlarged prostate without nodularity.

Based on the long-term PSA suppression data reported by Etzioni et al. (2005), which of the following most accurately represents this patient's corrected ("true") PSA value for the purpose of prostate cancer screening?

A. 4.0 ng/mL (multiplication factor of 1.15)

B. 7.0 ng/mL (multiplication factor of 2.0)

C. 8.05 ng/mL (multiplication factor of 2.3)

D. 8.75 ng/mL (multiplication factor of 2.5)

Rationale: Etzioni et al. (Urology, 2005) demonstrated that PSA suppression by 5-alpha reductase inhibitors is time-dependent and progressive with prolonged therapy. Specifically, a correction factor of approximately 2.3 should be applied for men on therapy for 2 years, whereas a factor of 2.5 is more appropriate for men on long-term therapy of 7 years or more. Therefore, this patient's corrected PSA is 3.5 × 2.5 = 8.75 ng/mL

A 62-year-old man is referred to your clinic with a persistently elevated serum PSA of 5.8 ng/mL (confirmed on repeat testing). He has no significant family history and an unremarkable digital rectal examination. A multiparametric MRI of the prostate is obtained and reported as PI-RADS 2 (no suspicious lesion). His prostate volume is 32 cc, yielding a PSA density of 0.18 ng/mL/cc.

According to the 2026 AUA/SUO Guideline on the Early Detection of Prostate Cancer, which of the following is the most appropriate next step?

A. Repeat the MRI in 6 months and defer biopsy pending imaging reassessment.

B. Proceed with systematic prostate biopsy given the elevated PSA density and persistent risk of clinically significant disease.

C. Initiate empiric therapy with a 5-alpha reductase inhibitor and monitor PSA response.

D. Reassure the patient and continue routine PSA surveillance at annual intervals, as the negative MRI excludes clinically significant cancer.

E. Obtain a polygenic risk score (PRS) to guide the decision regarding biopsy.

Rationale: The 2026 AUA/SUO Guideline issues a Moderate Recommendation (Evidence Level: Grade C) that in patients with a negative MRI (PI-RADS 1-2) who remain at elevated risk for Grade Group ≥2 prostate cancer, clinicians should proceed with systematic biopsy. PSA density is the strongest clinical predictor of clinically significant disease in MRI-negative cases; a threshold of ≥0.15 ng/mL/cc significantly increases the probability of harboring clinically significant cancer. Routine surveillance alone is inadequate in this setting, and PRS is not recommended to independently direct biopsy decisions outside of structured screening programs. Therefore the correct answer is B.

A 55-year-old asymptomatic man presents for prostate cancer screening following a shared decision-making discussion. He has no urinary complaints and no family history of prostate malignancy. He asks whether a digital rectal examination (DRE) should be performed as part of his screening evaluation.

Based on the 2026 AUA/SUO Guideline, which of the following most accurately reflects the current recommendation regarding the use of DRE in this setting?

A. DRE should be performed as the first-line screening test, as it has a higher positive predictive value than PSA in asymptomatic individuals.

B. DRE should routinely replace PSA in asymptomatic patients to minimize overdiagnosis of indolent disease.

C. DRE should not be used as a first-line or replacement screening test for PSA in asymptomatic patients, but may be used alongside PSA to help establish the risk of clinically significant prostate cancer.

D. DRE is mandatory at every screening visit and must be performed prior to PSA testing to enhance diagnostic yield.

E. DRE is contraindicated in asymptomatic screening given its documented negative impact on patient adherence.

Rationale: The 2026 AUA/SUO Guideline explicitly states that DRE should not be used as a first-line screening test prior to PSA, nor as a replacement for PSA, in otherwise asymptomatic patients. A recent meta-analysis demonstrated that adding DRE to PSA did not significantly improve positive predictive value (PPV of DRE: 0.21 vs PSA: 0.22; combined: 0.19). Nonetheless, the Guideline offers a Conditional Recommendation (Evidence Level: Grade C) that DRE may be used adjunctively with PSA to help establish the risk of clinically significant prostate cancer. Furthermore, survey data indicate that requiring up-front DRE may deter nearly a quarter of patients from undergoing prostate cancer screening. Therefore the correct answer is C

Until next Week 📬,

PSAWeekly team 🩺

_{[email protected]}